SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Atul receives USFDA approval for Dapsone manufacture facility

15 Jan 2015 Evaluate

Atul’s Dapsone manufacture facility located at Valsad in state of Gujarat has been approved by the US Food and Drug Administration (USFDA).

The company has two business segments, namely, ‘Life Science Chemicals’ and ‘Performance and Other Chemicals’. The Life Science Chemical segment comprises several manufacturing facilities which also include Dapsone manufacture facility.

Atul is a member of Lalbhai Group, one of the oldest business houses of India, with interests mainly in textiles and chemicals. The Group is strongly committed to serve the society in the fields of education, health as well as culture.

Atul Share Price

6723.35 62.55 (0.94%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
BASF India 3739.05
Tata Chemicals 707.80
SRF 2541.95
Pidilite Inds. 1402.25
Deepak Nitrite 1731.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×